Celularity Inc(CELU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,638 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CELU Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Celularity Inc (CELU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CELU at 22.4/100 on a 32-signal composite quality model, placing it at rank #2,638 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.4) and profitability (4.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Celularity Inc reports quarterly revenue of $4.1M, net income of $-24.4M, free cash flow of $-5.1M. Top institutional holders of CELU by reported 13-F value include C V STARR & CO, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CELU trades on the Nasdaq exchange and files with the SEC under CIK 1752828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celularity Inc directly from SEC EDGAR.
Revenue
Q4 2025
$4.1M
Net Income
Q4 2025
$-24.4M
Free Cash Flow
Q4 2025
$-5.1M
Get alerted when CELU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Celularity Inc including:
Top Institutional Holders of CELU
C V STARR & CO INC
$1.0M764,069 shVANGUARD CAPITAL MANAGEMENT LLC
$826.1K621,105 shGEODE CAPITAL MANAGEMENT, LLC
$254.2K191,076 shBlackRock, Inc.
$169.6K127,501 shVANGUARD FIDUCIARY TRUST CO
$106.2K79,874 shSTATE STREET CORP
$76.9K57,830 shValmark Advisers, Inc.
$66.5K49,983 shNORTHERN TRUST CORP
$58.7K44,163 shHB Wealth Management, LLC
$53.8K40,415 shBiltmore Family Office, LLC
$46.5K35,000 sh
| Fund | Value | Shares |
|---|---|---|
| C V STARR & CO INC | $1.0M | 764,069 |
| VANGUARD CAPITAL MANAGEMENT LLC | $826.1K | 621,105 |
| GEODE CAPITAL MANAGEMENT, LLC | $254.2K | 191,076 |
| BlackRock, Inc. | $169.6K | 127,501 |
| VANGUARD FIDUCIARY TRUST CO | $106.2K | 79,874 |
| STATE STREET CORP | $76.9K | 57,830 |
| Valmark Advisers, Inc. | $66.5K | 49,983 |
| NORTHERN TRUST CORP | $58.7K | 44,163 |
| HB Wealth Management, LLC | $53.8K | 40,415 |
| Biltmore Family Office, LLC | $46.5K | 35,000 |
More Healthcare Companies
View all Healthcare →Put CELU on your watchlist
Track score changes the day Celularity Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CELU a good stock to buy?
13F Pro's AI-powered analysis of Celularity Inc (CELU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CELU are available on the CELU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CELU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CELU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Celularity Inc's investment landscape.